Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis
Authors:
- Bernard F ColeBCBernard F Cole
- Richard D GelberRGRichard D Gelber
- Shari GelberSGShari Gelber
- Alan S CoatesACAlan S Coates
- Aron GoldhirschAGAron Goldhirsch
- 1 July 2001
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 358 (9278) , 277-286
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Subsets within the chemotherapy overviewThe Lancet, 1998
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survivalThe Lancet, 1996
- A quality‐adjusted survival meta‐analysis of adjuvant chemotherapy for premenopausal breast cancerStatistics in Medicine, 1995
- Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast CancerAnnals of Internal Medicine, 1991
- Quality adjusted survival analysisStatistics in Medicine, 1990
- Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.Journal of Clinical Oncology, 1989
- Utility approach to measuring health-related quality of lifeJournal of Chronic Diseases, 1987
- Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles.Journal of Clinical Oncology, 1983